{
    "nctId": "NCT04480814",
    "briefTitle": "Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC",
    "officialTitle": "A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue Samples of Patients With Metastatic ER+/HER2- Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Clinical performance of PIK3CA kit in CTCs, plasma and tumor tissue samples of metastatic breast cancer patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female aged \u2265 18 years of age.\n2. Histological confirmed ER+/HER2- metastatic Breast Cancer prior to beginning a treatment\n3. Life expectancy permits participation to the study.\n4. Available tumor tissue sample for molecular analysis.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Female younger than 18 years old.\n2. History of another malignancy within 3 years or current 2nd primary malignancy.\n3. Patients that have not signed the informed consent.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}